Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, Glucose Monitoring, Other Feb 12 | 2024Novo Settles Counterfeit Semaglutide Lawsuits; New Ph2 Oral GLP-1RA Study from Jiangsu Hengrui Pharmaceuticals; CSL Fails CSL112 Pivotal Trial; Eversense E3 CGM Medicare Coverage; Biocon CY Q4 ’23 (FY Q3 ’24) EarningsPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Glucose Monitoring, Insulin Delivery, Other Feb 08 | 2024Dexcom Q4 ’23 and FY ’23 EarningsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, SGLT2i Feb 08 | 2024AZ and Viking Q4 ‘23 Earnings; Madrigal Publishes MAESTRO-NASH ResultsPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other Feb 07 | 2024Amgen, Arrowhead, and Vertex Q4 ‘23 Earnings; Dexcom Launches Dexcom ONE+; O5 Receives CE Mark for Libre 2 Plus Integration; Brian Hansen Appointed Ascensia CGM President; Scholar Rock Preclinical Data for ObesityPurchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, GLP-1RA, Other, SGLT2i Feb 06 | 2024Mounjaro and Zepbound Launch Updates; Tirzepatide Ph2 MASH Data; Lilly’s Smart Insulin Enters Ph1; Lilly Q4 ’23 Earnings UpdatePurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other Feb 05 | 2024Novo Acquires Catalent for Manufacturing Capacity; Amgen Publishes MariTide Results; Beyond Type 1 Launches National Initiative for DiabetesPurchase Blast
$599
Posted in: Glucose Monitoring, Other Feb 02 | 2024Regeneron Q4 ’23 Earnings; Supersapiens Launches Funding CampaignPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Other Feb 01 | 2024Novo London, Merck, Roche, and Sanofi Q4 ’23 Earnings; FDA Clears NeuroBo’s Obesity INDPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, SGLT2i Jan 31 | 2024Trinity Biotech Acquires Waveform CGM Assets; Novartis Q4 ’23 Earnings; Abbott Launches Nutrition Drink for Weight LossPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Other Jan 31 | 2024New Novo Once-Monthly Dual-Agonist; Icodec Delayed; Novo Q4 ’23 Earnings UpdatesPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucagon, Glucose Monitoring, Insulin Delivery, Other Jan 30 | 2024New Insulin Patch Pump; Pfizer Q4 ‘23 Earnings; Lilly Initiates Ph2 LA Amylin Obesity Trial; Lilly Trying to Get Mounjaro Reimbursed in GermanyPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA Jan 29 | 2024Roche Completes Carmot AcquisitionPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Insulin Delivery, Other Jan 25 | 2024Mounjaro KwikPen Approved in UK; Biocorp Receives 510(K) Clearance for SoloSmart; Novo Initiates Second Ph3 Cagrisema T2DM Trial; Mounjaro 12.5mg Added to FDA Shortage Database; Counterfeit Ozempic Causes Cases of HypoglycemiaPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, Glucose Monitoring, Insulin Delivery Jan 24 | 2024Abbott Q4 ‘23 Earnings; Sciwind Oral GLP-1RA Ph1 DataPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, SGLT2i Jan 23 | 2024Novo Partners for Oral Obesity Asset; Scholar Rock Announces IND Clearance for Obesity; JNJ Q4 ’23 EarningsPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, DPP-IVi, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Other, SGLT2i Jan 22 | 2024SELECT up for CHMP Opinion?; January CHMP Agenda; Akero Initiates Ph3 EFX MASH TrialPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Other Jan 19 | 2024Dexcom to Build EU Manufacturing Plant; FDA Finds Manufacturing Lapses at Lilly PlantPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring Jan 17 | 2024Lilly to Launch Mounjaro in EU; FDA Posts Libre 3 Android App Recall; Novo Initiates Ph1 Cagrisema Study in Weight Loss MechanismsPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, SGLT2i Jan 16 | 2024Novo Resumes Shipments of Wegovy doses in US; Amgen to Acquire Cytokinetics?; Dexcom G7 Integrated with t:slim X2 OUS; Novo Initiates Additional Ph3 Ziltivekimab Trial in HF; BI Expands Greece Manufacturing FacilityPurchase Blast
$599
Posted in: GLP-1RA, Insulin Delivery, Other, SGLT2i Jan 11 | 2024JPM 2024 Day 4: MDGL, LXRX, MNKD, AKBA, and XERS; Novartis No Longer Pursuing Cytokinetics AcquisitionPurchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
